Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Russell Bingham

Interventional Pain Medicine West Columbia, SC Physician Assistant

NPI 1275270654 CMS profile 11324144

3227 Sunset Blvd Ste F102, West Columbia, SC 29169

Open in the dashboard

General payments

$3,181

186 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Bingham of West Columbia, SC is reported in the CMS Open Payments database as having received $3,181 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $580 32
2024 General $958 56
2023 General $1,307 78
2022 General $337 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Bingham
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Russell Bingham were reported at $580. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Russell Bingham Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $337 $605 $187–$1,924 $149
2023 $1,307 $671 $195–$1,915 $160
2024 $958 $684 $206–$1,837 $164
2025 $580 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Forte Bio-Pharma LLC $1,115 66 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $958 48 payments
  3. CutisPharma, Inc. $489 40 payments
  4. Collegium Pharmaceutical, Inc. $188 10 payments
  5. IBSA Pharma Inc. $153 8 payments
  6. Lilly USA, LLC $40 2 payments
  7. Scilex Pharmaceuticals Inc. $36 2 payments
  8. Vertex Pharmaceuticals Incorporated $35 2 payments
  9. Boston Scientific Corporation $29 1 payment
  10. AbbVie, Inc. $25 1 payment
  11. Other $112 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,181 186 payments
Products named General payments · program years 2022–2025
  1. PROLATE Pain $1,065 65 payments
  2. PROLATE Pain $1,065 65 payments
  3. PROLATE Pain $1,065 65 payments
  4. NALOCET $1,065 65 payments
  5. RELISTOR Gastroenterology $935 47 payments
  6. RELISTOR Gastroenterology $864 44 payments
  7. PROLATE Pain $680 42 payments
  8. TANLOR $386 23 payments
  9. Horizant Sleep $258 22 payments
  10. HORIZANT Cerebrovascularcns $231 18 payments
  11. Other $868 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

7,017

Median for Interventional Pain Management: 1,220

Drug cost

$748,811

Median for Interventional Pain Management: $39,344

Branded share of claims

44.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 269 $220,062
Oxycontin Oxycodone Hcl Brand 83 $78,942
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 989 $53,285
Oxycodone Hcl Generic 1,031 $35,952
Hysingla Er Hydrocodone Bitartrate Brand 38 $35,238
Relistor Methylnaltrexone Bromide Brand 16 $33,857
Ubrelvy Ubrogepant Brand 13 $26,676
Nucynta Er Tapentadol Hcl Brand 28 $26,163
Oxymorphone Hcl Er Oxymorphone Hcl Brand 28 $23,407
Morphine Sulfate Er Morphine Sulfate Brand 773 $23,203

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $316
$316 16 —
PROLATE
  • Forte Bio-Pharma LLC $281
$281 — —
HORIZANT
  • CutisPharma, Inc. $231
$231 — —
NALOCET
  • Forte Bio-Pharma LLC $70
$70 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $23
$23 269 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record